2015
DOI: 10.1038/nmeth.3366
|View full text |Cite
|
Sign up to set email alerts
|

Isotope-targeted glycoproteomics (IsoTaG): a mass-independent platform for intact N- and O-glycopeptide discovery and analysis

Abstract: Protein glycosylation is a heterogeneous post-translational modification (PTM) that plays an essential role in biological regulation. However, the diversity found in glycoproteins has undermined efforts to describe the intact glycoproteome via mass spectrometry (MS). We present IsoTaG, a mass-independent chemical glycoproteomics platform for characterization of intact, metabolically labeled glycopeptides at the whole-proteome scale. In IsoTaG, metabolic labeling of the glycoproteome is combined with (i) chemic… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

6
322
1

Year Published

2016
2016
2019
2019

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 232 publications
(330 citation statements)
references
References 48 publications
6
322
1
Order By: Relevance
“…We believe that this constitutes the first broad proteomic analysis of O-GlcNAc-modified proteins in primary human T cells. Many of the proteins that we identified appeared in prior proteomics studies (55,(76)(77)(78), supporting the validity of our results. However, we also identified novel O-GlcNAc substrates, including ARNT, HCLS1, ZAP-70, SHIP1, LCK, and PI3K.…”
Section: Discussionsupporting
confidence: 87%
“…We believe that this constitutes the first broad proteomic analysis of O-GlcNAc-modified proteins in primary human T cells. Many of the proteins that we identified appeared in prior proteomics studies (55,(76)(77)(78), supporting the validity of our results. However, we also identified novel O-GlcNAc substrates, including ARNT, HCLS1, ZAP-70, SHIP1, LCK, and PI3K.…”
Section: Discussionsupporting
confidence: 87%
“…Although the majority of these are nuclear and cytoplasmic proteins (Figure 2), 23% were associated with the secretory pathway. GlcNAz is the primary endpoint for Ac 4 GalNAz labeling in cell culture (95% of incorporated label (43)), but identified glycoproteins falling in the secretory category may bear glycans other than O-GlcNAz as Ac 4 GalNAz has the potential to label multiple types of glycans at O-glycosites (e.g., O-GalNAz) (42). While it is rare to observe the Tn antigen in healthy human T cells, it is possible for activated human T cells to display the Tn antigen (47) or for an extracellular glycoprotein to become intracellular through the ERAD pathway.…”
Section: Discussionmentioning
confidence: 99%
“…Thus, for each glycopeptide sample an HCDpdETD scouting run was collected, followed by an inclusion list-driven run with an HCD/ETD/CID duty cycle ( Figure 1C). In previous work on an LTQ-Orbitrap XL, a 4-fold improvement in glycopeptide selection using the inclusion list was found (42). Using an LTQOrbitrap Elite, a HCDpdETD method yielded the most glycopeptide assignments, with the majority of glycopeptide assignments derived from HCD alone (50% for trypsin digests, 70% for chymotrypsin digests).…”
Section: Identification Of Over 2000 O-glcnaz Containing Peptides Frmentioning
confidence: 96%
See 1 more Smart Citation
“…Solid phase hydrazide-based glycopeptide capture has also seen developments (48) and applications (see Table I), but this approach is most commonly used in conjunction with peptide N-glycosidase F-catalyzed release and analysis of formerly N-glycosylated peptides and does not satisfy our definition of glycoproteomics. Other new enrichment methods of interest include the metabolic incorporation of N-azido sugars into N-glycopeptides to facilitate their specific enrichment and detection (84,85). The selective precipitation of glycopeptides by acetone (86), use of size exclusion chromatography (87,88) and the combined use of porous graphitized carbon (PGC) and reversed phase (RP) (89) and titanium dioxide (90) solid phase extraction (SPE) for efficient enrichment of glycopeptides and sialoglycopeptides, respectively, are also promising developments.…”
mentioning
confidence: 99%